DNA Services Capabilities

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES.

DNA Services Capabilities

Proven Design Strategies Validating Early-Stage Concepts.

CELL & GENE | RNA | BIOLOGICS

Plasmid DNA Services for Viral Vector Production

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Plasmid DNA Quality as a Critical Determinant of Therapeutic Viability

The architectural integrity of plasmid DNA is the starting point for developing viable advanced therapeutics and complex biologics. The design, purity, and scalability of this initial material directly influences downstream viral vector yield, batch consistency, and the ultimate success of an IND submission. Our approach applies proven intelligence in plasmid engineering to accelerate the development of next-generation therapies by building quality into the process from its origin.

A manufacturing process for AAV, lentivirus, or adenovirus is only as robust as its starting components. Sub-optimal plasmid quality can introduce variability that compromises preclinical data and complicates regulatory filings. We focus on producing highly characterized, purified plasmid DNA to serve as a reliable foundation for both research-grade and large-scale vector production campaigns.

Plasmid Engineering and Manufacturing Services for Viral Vector Systems

Our DNA services are configured to support the specific requirements of viral vector systems.

  • Plasmid Design & Optimization: We perform optimization and vector backbone selection tailored for high-titer expression in established platforms, including both adherent and suspension HEK293 cell lines.
  • Component Production: We generate the distinct plasmid components required for viral vector packaging: helper plasmids, rep/cap plasmids for specific AAV serotypes and the ITR-containing plasmid for the gene of interest (GOI).
  • Scalable Manufacturing: Production scales are matched to program needs, from quantities sufficient for initial research to large scale quantities for toxicology studies for extensive in vivo evaluations.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Mitigation of Preclinical Variability Through Starting Material Control

Ambiguous outcomes in preclinical biodistribution and efficacy evaluations can often be traced back to inconsistencies in the vector production process, which may originate with the plasmid DNA itself. Ensuring the starting material is well-defined and consistently produced is a primary step in minimizing clinical risk and generating clear, translatable data packages for regulatory review.

Analytical Characterization and Lot Release Criteria

Every batch of plasmid DNA undergoes a panel of analytical release tests to confirm its suitability for vector production. These assays verify identity and sequence integrity through restriction digest analysis and sequencing, confirm high purity via agarose gel electrophoresis, and quantify concentration. This documentation provides a clear data trail for the starting material used in every vector lot, supporting the accelerated 18-24 month IND timelines our scientific team has consistently achieved.

These services are an integrated component of our broader Vector | CMC | Analytics Services, providing a solid foundation for subsequent process development and manufacturing.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities